ASX Life Sciences stocks: Here are 2 of the best!

ASX Life Sciences stocks discussed by Stuart Roberts as interest rates peak

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips on the top Stocks in ASX

When looking at ASX Life Sciences stocks, Stuart points out Neuren Pharmaceuticals (ASX:NEU), saying the company received FDA approval in March for trofinetide and that they are on the verge of developing a new drug. Stuart sees a promising future for the company, foreseeing its potential to become a major pharma firm once investors realise its potential.

He also his view on Botanix Pharmaceuticals (ASX:BOT), another company worth watching due to its potential FDA approval for a drug treating primary axillary hyperhidrosis, a condition affecting 10% of the population. He presents the numerous companies maturing in the life sciences sector, moving beyond approval into the commercialisation stage.

Stuart recommends seeking expert guidance, accessing research, diversifying risk and ensuring only a fraction of your portfolio is exposed to these potentially volatile ASX Life Sciences stocks.

Stuart Roberts talking Life Sciences on AusBiz on 28 July 2023

Stocks Down Under Concierge is here to help you pick winning stocks!

The team at Stocks Down Under have been in the markets since the mid-90s and we have gone through many ups and downs. We have written about every sector, including ASX Life Sciences stocks!

Our Concierge BUY and SELL service picks the best stocks on ASX. We won’t just tell you what to buy – we give you a buy range, price target and stop loss level in order to maximise total returns. And we will only recommend very high conviction stocks where substantial due diligence has been conducted.

Our performance is well ahead of the ASX200 and All Ords.

You can try out Concierge … for FREE.

GET A FREE TRIAL TO CONCIERGE TODAY

There’s no credit card needed – the trial expires automatically.